BR112021020964A2 - Inibidor seletivo de quinase jak1 - Google Patents
Inibidor seletivo de quinase jak1Info
- Publication number
- BR112021020964A2 BR112021020964A2 BR112021020964A BR112021020964A BR112021020964A2 BR 112021020964 A2 BR112021020964 A2 BR 112021020964A2 BR 112021020964 A BR112021020964 A BR 112021020964A BR 112021020964 A BR112021020964 A BR 112021020964A BR 112021020964 A2 BR112021020964 A2 BR 112021020964A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitor
- compounds
- selective jak1
- jak1 kinase
- formula
- Prior art date
Links
- 101150079478 jak1 gene Proteins 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083376 | 2019-04-19 | ||
| PCT/CN2020/085338 WO2020211839A1 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020964A2 true BR112021020964A2 (pt) | 2021-12-14 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020964A BR112021020964A2 (pt) | 2019-04-19 | 2020-04-17 | Inibidor seletivo de quinase jak1 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220220096A1 (enExample) |
| EP (1) | EP3956322B1 (enExample) |
| JP (1) | JP7555959B2 (enExample) |
| KR (1) | KR20220003537A (enExample) |
| CN (1) | CN113710664B (enExample) |
| AR (1) | AR118729A1 (enExample) |
| AU (1) | AU2020258619B2 (enExample) |
| BR (1) | BR112021020964A2 (enExample) |
| CA (1) | CA3134174A1 (enExample) |
| DK (1) | DK3956322T3 (enExample) |
| ES (1) | ES3031576T3 (enExample) |
| MX (1) | MX2021012749A (enExample) |
| PT (1) | PT3956322T (enExample) |
| TW (1) | TW202104215A (enExample) |
| WO (1) | WO2020211839A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7613778B2 (ja) * | 2020-11-26 | 2025-01-15 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) * | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| HRP20230069T1 (hr) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Selektivni inhibitori jak1 |
| WO2020057669A1 (zh) * | 2018-09-21 | 2020-03-26 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
-
2020
- 2020-04-17 TW TW109112994A patent/TW202104215A/zh unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619B2/en active Active
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 US US17/604,442 patent/US20220220096A1/en active Pending
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES3031576T3 (en) | 2025-07-09 |
| EP3956322A1 (en) | 2022-02-23 |
| US20220220096A1 (en) | 2022-07-14 |
| PT3956322T (pt) | 2025-06-04 |
| EP3956322B1 (en) | 2025-05-14 |
| KR20220003537A (ko) | 2022-01-10 |
| WO2020211839A1 (en) | 2020-10-22 |
| JP2022529061A (ja) | 2022-06-16 |
| CA3134174A1 (en) | 2020-10-22 |
| CN113710664A (zh) | 2021-11-26 |
| AR118729A1 (es) | 2021-10-27 |
| TW202104215A (zh) | 2021-02-01 |
| DK3956322T3 (da) | 2025-06-16 |
| JP7555959B2 (ja) | 2024-09-25 |
| AU2020258619B2 (en) | 2025-10-23 |
| MX2021012749A (es) | 2021-11-18 |
| CN113710664B (zh) | 2024-01-26 |
| EP3956322A4 (en) | 2023-05-03 |
| AU2020258619A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021020964A2 (pt) | Inibidor seletivo de quinase jak1 | |
| BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
| BR112022007867A2 (pt) | Degradadores de pequena molécula de helios e métodos de uso | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| BR112019002610A2 (pt) | piridopirimidinonas inibidoras de cdk2/4/6 | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
| GEAP202416075A (en) | New macrocyclic lrrk2 kinase inhibitors | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| JOP20190174B1 (ar) | مثبطات jak1 انتقائية | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
| TN2018000043A1 (en) | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors | |
| BR112015015635A8 (pt) | composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão | |
| BR112015014590A2 (pt) | composto; composição farmacêutica; estojo ou farmacêutico empacotado; método de inibição de prmt5; método de alteração da expressão de genes; método de alteração da transcrição; e método de tratamento ou prevenção de um distúrbio mediado por prmt5 | |
| NO20090783L (no) | Pyrimidonforbindelser som inhibitorer av GSK-3 | |
| ECSP12011910A (es) | Derivados de imidazopiridina como inhibidores de jak | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| BR112014002675A2 (pt) | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" | |
| BR112019024322A2 (pt) | Compostos e composições terapêuticos e métodos de uso dos mesmos | |
| BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
| PH12017501699A1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |